August, Dubai – AGBL Afrique has announced that its customer Center of Biotechnology of Sfax (CBS) has successfully completed its first full SARS-CoV2 sequencing in Tunisia. The sequencing of the virus was performed at the CBS in collaboration with Habib Bourguiba and Fatouma Bourguiba Virology Departments using an NGS sequencing technologies supplied and supported by AGBL Afrique.
Mr. Mohamed Ben Marzouk, a senior Area Manager at AGBL Afrique, expressed his satisfaction, “We’re proud to be a part of the efforts to complete the first full SARS-CoV2 sequence in Tunisia, our team has been working diligently to support national and regional efforts to combat the virus.”
Professor Saber Masmoudi, Director of Laboratoire de Procédés de Criblage Moléculaire et Cellulaire at CBS, said, “We are extremely happy to see our efforts come to fruition by completing this landmark research goal, and we are thankful for the support and assistance that the AGBL Afrique team has given us.”
Professor Ahmed Rebai, Coordinator of the project, added “This is just a first milestone and others are to come with more NGS sequencing of viral and host genomes”.
About AGBL Afrique
AGBL Afrique is a member of the AGBL group of companies, the largest biomedical distribution group in the Middle East, Africa, and Asia region. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic centres in emerging healthcare markets. AGBL Afrique is based in Tunis and covers North and West Africa through a network of offices and field staff.
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
